Jerrold L Vitek, Roshini Jain, Lilly Chen, Alexander I Tröster, Lauren E Schrock, Paul A House, Monique L Giroux, Adam O Hebb, Sierra M Farris, Donald M Whiting, Timothy A Leichliter, Jill L Ostrem, Marta San Luciano, Nicholas Galifianakis, Leo Verhagen Metman, Sepehr Sani, Jessica A Karl, Mustafa S Siddiqui, Stephen B Tatter, Ihtsham Ul Haq, Andre G Machado, Michal Gostkowski, Michele Tagliati, Adam N Mamelak, Michael S Okun, Kelly D Foote, Guillermo Moguel-Cobos, Francisco A Ponce, Rajesh Pahwa, Jules M Nazzaro, Cathrin M Buetefisch, Robert E Gross, Corneliu C Luca, Jonathan R Jagid, Gonzalo J Revuelta, Istvan Takacs, Michael H Pourfar, Alon Y Mogilner, Andrew P Duker, George T Mandybur, Joshua M Rosenow, Scott E Cooper, Michael C Park, Suketu M Khandhar, Mark Sedrak, Fenna T Phibbs, Julie G Pilitsis, Ryan J Uitti, Philip A Starr
BACKGROUND: Deep brain stimulation (DBS) of the subthalamic nucleus is an established therapeutic option for managing motor symptoms of Parkinson's disease. We conducted a double-blind, sham-controlled, randomised controlled trial to assess subthalamic nucleus DBS, with a novel multiple independent contact current-controlled (MICC) device, in patients with Parkinson's disease. METHODS: This trial took place at 23 implanting centres in the USA. Key inclusion criteria were age between 22 and 75 years, a diagnosis of idiopathic Parkinson's disease with over 5 years of motor symptoms, and stable use of anti-parkinsonian medications for 28 days before consent...
June 2020: Lancet Neurology